Springer Science and Business Media LLC
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases
Springer Science and Business Media LLC - Tập 11 - Trang 514-527 - 2016
Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT) is an aggressive extranodal non-Hodgkin lymphoma most commonly occurring in East Asia and Latin America but with increasing incidence in the United States. Data on epidemiology, disease presentation, and outcome for European and North American (“Western”) cases are very limited. We review published landmark clinical studies on ENKTL-NT in the We...... hiện toàn bộ
10 Years of Preparedness by the Radiation Injury Treatment Network
Springer Science and Business Media LLC - Tập 12 - Trang 39-43 - 2017
The Radiation Injury Treatment Network (RITN) began in 2006 with the ambitious vision to provide a resource to help with the surge of casualties following a mass casualty incident with marrow toxic injuries. Through the efforts of the National Marrow Donor Program and American Society for Blood and Marrow Transplantation with the support of the Office of Naval Research, the initial 13 hospitals an...... hiện toàn bộ
Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm
Springer Science and Business Media LLC - Tập 15 - Trang 168-176 - 2020
The treatment landscape of treatment-naive chronic lymphocytic leukemia (TN-CLL) is rapidly evolving. As more and more new drugs and combinations are becoming part of therapeutic armamentarium, it becomes highly pertinent to understand the evidence for each of the treatment options to select the right drug for the right patient. We summarize the recent data of the available frontline treatment opt...... hiện toàn bộ
Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?
Springer Science and Business Media LLC - - 2006
The myelodysplastic syndromes (MDS) can be divided into "early" and "advanced" disease by evaluation of prognostic variables such as the number of cytopenias, karyotype, and percentage of myeloblasts. Patients with an isolated interstitial deletion of chromosome 5q31 represent a distinct subset who may derive particular benefit from immunomodulatory drugs. Goals of therapy for early MDS focus on h...... hiện toàn bộ
Curing Chronic Myeloid Leukemia
Springer Science and Business Media LLC - Tập 7 - Trang 103-108 - 2012
The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about...... hiện toàn bộ
Polatuzumab Vedotin: a New Target for B Cell Malignancies
Springer Science and Business Media LLC - Tập 15 - Trang 125-129 - 2020
Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Polatuzumab vedotin recently received its first FDA approval in combination with bendamustine and rituximab f...... hiện toàn bộ
Predicting the response of CML patients to tyrosine kinase inhibitor therapy
Springer Science and Business Media LLC - Tập 4 Số 2 - Trang 59-65 - 2009
Relapsed T Cell ALL: Current Approaches and New Directions
Springer Science and Business Media LLC - Tập 14 - Trang 83-93 - 2019
Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL. Although nelarabine is the only agent approved specifically for ...... hiện toàn bộ
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
Springer Science and Business Media LLC - Tập 14 - Trang 31-38 - 2019
While the traditional gold standard for demonstrating clinical benefit of a therapy has been to show prolongation of overall survival (OS), there are multiple factors which can hinder the use of OS as a primary endpoint in randomized clinical trials (RCTs). Here, we analyze recent myeloma RCTs and evaluate the issues relevant to current and future myeloma RCT design. A review of recent phase III R...... hiện toàn bộ
Genetic Basis of MPN: Beyond JAK2-V617F
Springer Science and Business Media LLC - Tập 8 - Trang 299-306 - 2013
The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by genetic alterations, often affecting cytokine signaling and gene expression. This re...... hiện toàn bộ
Tổng số: 577
- 1
- 2
- 3
- 4
- 5
- 6
- 10